{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:49:03Z","timestamp":1790383743849,"version":"4.1.0"},"reference-count":112,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2013,6,12]]},"DOI":"10.4161\/hv.24129","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:23:51Z","timestamp":1365204231000},"page":"1241-1253","source":"Crossref","is-referenced-by-count":196,"title":["Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future"],"prefix":"10.1080","volume":"9","author":[{"given":"Johan","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"N\u00e6ss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Aaberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"McNicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"O'Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Rosenqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,11,3]]},"reference":[{"key":"R1","first-page":"163","article-title":"Memoire sur le maladie qui a regne a Geneva au printemps de 1805","volume":"11","author":"Vieusseux","year":"1805","journal-title":"J Med Clin Pharm"},{"key":"R2","first-page":"65","article-title":"A history of a singular and very noted disease, which lately made its appearance in Medfield","volume":"1","author":"Danielson","year":"1806","journal-title":"Medical and Agricultural Register"},{"key":"R3","first-page":"573","article-title":"Ueber die aetiologie der akuten meningitis cerebro-spinal","volume":"5","author":"Weichselbaum","year":"1887","journal-title":"Fortschr Med"},{"key":"R4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1084\/jem.17.5.553","article-title":"The results of the serum treatment in thirteen hundred cases of epidemic meningits","volume":"17","author":"Flexner","year":"1913","journal-title":"J Exp Med"},{"key":"R5","first-page":"44","article-title":"The outbreak of cerebrospinal fever at Salisbury in 1914-15","volume":"10","author":"Greenwood","year":"1917","journal-title":"Proc R Soc Med"},{"key":"R6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(98)00279-7","article-title":"Uncloaking the meningococcus: dynamics of carriage and disease","volume":"353","author":"Stephens","year":"1999","journal-title":"Lancet"},{"key":"R7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","article-title":"Conquering the meningococcus","volume":"31","author":"Stephens","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"R8","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"R9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1099\/jmm.0.47599-0","article-title":"Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease","volume":"57","author":"de Souza","year":"2008","journal-title":"J Med Microbiol"},{"key":"R10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0072-9752(08)02128-3","article-title":"Chapter 28: a history of bacterial meningitis","volume":"95","author":"Tyler","year":"2010","journal-title":"Handb Clin Neurol"},{"key":"R11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/bmj.327.7415.596","article-title":"Case fatality rates for meningococcal disease in an English population, 1963-98: database study","volume":"327","author":"Goldacre","year":"2003","journal-title":"BMJ"},{"key":"R12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s100960050162","article-title":"Trend in incidence and case fatality of meningococcal disease over 16 years in Northern Denmark","volume":"17","author":"S\u00f8rensen","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0264-410X(00)00333-9","article-title":"Development of natural immunity to Neisseria meningitidis.","volume":"19","author":"Pollard","year":"2001","journal-title":"Vaccine"},{"key":"R14","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMcp063561","article-title":"Clinical practice. Prevention of meningococcal disease","volume":"355","author":"Gardner","year":"2006","journal-title":"N Engl J Med"},{"key":"R16","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"R18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3181\/00379727-169-41306","article-title":"Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135","volume":"169","author":"Hankins","year":"1982","journal-title":"Proc Soc Exp Biol Med"},{"key":"R19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1128\/IAI.34.3.725-732.1981","article-title":"Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults","volume":"34","author":"Griffiss","year":"1981","journal-title":"Infect Immun"},{"key":"R20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis.","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"R21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1586\/erv.09.30","article-title":"Challenges and progress in the development of a serogroup B meningococcal vaccine","volume":"8","author":"Lewis","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","author":"Gasparini","year":"2011","journal-title":"Hum Vaccin"},{"key":"R23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IDR.S12716","article-title":"Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease","volume":"4","author":"Br\u00f6ker","year":"2011","journal-title":"Infect Drug Resist"},{"key":"R24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R25","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","article-title":"Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine","volume":"30","author":"LaForce","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"R27","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"R28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"R29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"key":"R30","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines-an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R32","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"R33","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"R34","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.vaccine.2005.12.059","article-title":"Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks","volume":"25","author":"Taha","year":"2007","journal-title":"Vaccine"},{"key":"R35","first-page":"69","article-title":"Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells","volume":"89","author":"Helting","year":"1981","journal-title":"Acta Pathol Microbiol Scand C"},{"key":"R36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/JB.146.1.69-78.1981","article-title":"Five structural classes of major outer membrane proteins in Neisseria meningitidis.","volume":"146","author":"Tsai","year":"1981","journal-title":"J Bacteriol"},{"key":"R37","unstructured":"Frasch CE. Meningococcal Vaccines: Past, Present and Future. In: Cartwright K, editor. Meningococcal Disease. New York: John Wiley & Sons, 1995: 245-83."},{"key":"R38","unstructured":"Frasch C, Van Alphen L, Holst J, Poolman J, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard AJ, Maiden MC, editors. Meningococcal vaccines: methods and protocols. Totowa, New Jersey: Humana Press, 2001: 81-107."},{"key":"R39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00415494","article-title":"Human bactericidal antibody response to meningococcal outer membrane protein vaccines","volume":"53","author":"Zollinger","year":"1987","journal-title":"Antonie Van Leeuwenhoek"},{"key":"R40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/137.6.728","article-title":"Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans","volume":"137","author":"Zollinger","year":"1978","journal-title":"J Infect Dis"},{"key":"R41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.147.3.629","article-title":"Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model","volume":"147","author":"Frasch","year":"1978","journal-title":"J Exp Med"},{"key":"R42","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"R43","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"R44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R45","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"key":"R46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/CVI.00047-06","article-title":"Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine","volume":"13","author":"Feiring","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R47","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"key":"R48","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"R49","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.281.16.1541","article-title":"Serogroup B meningococcal disease: new outbreaks, new strategies","volume":"281","author":"Wenger","year":"1999","journal-title":"JAMA"},{"key":"R50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4","volume":"177","author":"Martin","year":"1998","journal-title":"J Infect Dis"},{"key":"R51","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.vaccine.2005.01.061","article-title":"From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease","volume":"23","author":"O\u2019Hallahan","year":"2005","journal-title":"Vaccine"},{"key":"R52","unstructured":"O'Hallahan J, Martin D, Oster P. An epidemic of group B meningococcal of disease controlled by a vaccine - the final chapter. 15th International PathogenicNeisseriaConference; 2006 September 10-15, 2006; Cairns, Australia; 2006. p. 42."},{"key":"R53","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1016\/j.vaccine.2008.08.062","article-title":"MeNZB vaccine and epidemic control: when do you stop vaccinating?","volume":"26","author":"Loring","year":"2008","journal-title":"Vaccine"},{"key":"R54","first-page":"pii=2262","article-title":"A \u201ctailor made\u201d vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand","volume":"7","author":"Holst","year":"2003","journal-title":"Euro Surveill"},{"key":"R55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"R56","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"key":"R57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"R58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/adc.2007.132571","article-title":"Phase II meningococcal B vesicle vaccine trial in New Zealand infants","volume":"94","author":"Jackson","year":"2009","journal-title":"Arch Dis Child"},{"key":"R59","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erv.11.32","article-title":"A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"10","author":"Su","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/cpr.11.128","article-title":"Advances in meningococcal vaccines","volume":"9","author":"Pizza","year":"2012","journal-title":"Clin Pract"},{"key":"R63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R64","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"R65","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"},{"key":"R66","unstructured":"Jansen KU, McNeil LK, Dragalin V, Anderson AS, Hoiseth SK, Arora A, et al. Bivalent recombinant LP2086 vaccine to provide broad protection againstNeisseria meningitidisB disease: Immunological correlates of protection and how to assess coverage against invasive MnB strains. In: van Alphen L, van Ley P, van den Dobbelsteen G, editors. 16th International PathogenicNeisseriaConference. Rotterdam, The Netherlands, 2008: abstract 064."},{"key":"R67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"R68","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"R69","unstructured":"Tyson J, Norman R. Fighting a Fearful Disease; Controlling New Zealand's meningococcal B epidemic. Institute of Policy Studies, Victoria University of Wellington, The Australian and New Zealand School of Government 2007."},{"key":"R70","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"key":"R71","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"R72","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","article-title":"Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them","volume":"3","author":"Holst","year":"2007","journal-title":"Hum Vaccin"},{"key":"R73","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"R74","unstructured":"Bjaering Hansen N, H\u00f8iby EA, Caugant DA, Fr\u00f8holm LO, Holst J, Tangen T, et al. Development and evaluation of experimental meningococcal B:4:P1.(7),4 outer membrane vaccines. In: Nassif X, Quentin-Millet M-J, Taha M-K, editors. 11th International PathogenicNeisseriaConference; 1998 November 1-6, 1998; Nice, France: Editions E.D.K.; 1998. p. 169."},{"key":"R75","unstructured":"Rosenqvist E, Bryn K, Harbak K, Holst J, H\u00f8iby EA, Kristiansen P, et al. Development of a tailor-made outer membrane vesicle vaccine against the group B meningococcal epidemic in New Zealand. In: Caugant, DA Wedege, E editors 13th International PathogenicNeisseriaConference; September 1-6, 2002 Oslo: Nordberg Aksidenstrykkeri AS; 2002 p64 2002."},{"key":"R76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/603552","article-title":"Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand","volume":"49","author":"Lennon","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R77","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"R78","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","article-title":"Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand","volume":"25","author":"Oster","year":"2007","journal-title":"Vaccine"},{"key":"R79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/14760584.3.1.77","article-title":"Serologic correlates of protection for evaluating the response to meningococcal vaccines","volume":"3","author":"Balmer","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"R81","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R82","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R83","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","article-title":"Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials","volume":"23","author":"Martin","year":"2005","journal-title":"Vaccine"},{"key":"R84","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R85","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"R86","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"R87","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/INF.0b013e318195205e","article-title":"Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine","volume":"28","author":"Wong","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R88","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1097\/01.inf.0000147645.53942.00","article-title":"The strategy to control New Zealand\u2019s epidemic of group B meningococcal disease","volume":"23","author":"O\u2019Hallahan","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R89","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.vaccine.2008.03.017","article-title":"The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand","volume":"26","author":"Tatley","year":"2008","journal-title":"Vaccine"},{"key":"R90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vaccin"},{"key":"R91","doi-asserted-by":"crossref","first-page":"B57","DOI":"10.1016\/j.vaccine.2011.12.093","article-title":"Considerations for controlling invasive meningococcal disease in high income countries","volume":"30","author":"Holst","year":"2012","journal-title":"Vaccine"},{"key":"R92","first-page":"48","article-title":"Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease","volume":"122","author":"O\u2019Hallahan","year":"2009","journal-title":"N Z Med J"},{"key":"R93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/adc.2007.125195","article-title":"Henoch-Sch\u00f6nlein purpura and meningococcal B vaccination","volume":"94","author":"Sexton","year":"2009","journal-title":"Arch Dis Child"},{"key":"R94","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.vaccine.2007.12.001","article-title":"The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand","volume":"26","author":"Stehr-Green","year":"2008","journal-title":"Vaccine"},{"key":"R95","first-page":"U2746","article-title":"The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand","volume":"120","author":"Stehr-Green","year":"2007","journal-title":"N Z Med J"},{"key":"R96","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","article-title":"Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease","volume":"25","author":"N\u00f8kleby","year":"2007","journal-title":"Vaccine"},{"key":"R97","first-page":"U1015","article-title":"The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic","volume":"117","author":"Sexton","year":"2004","journal-title":"N Z Med J"},{"key":"R98","first-page":"38","article-title":"Surveillance of vaccine breakthrough cases following MeNZB vaccination","volume":"121","author":"McNicholas","year":"2008","journal-title":"N Z Med J"},{"key":"R99","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R100","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1128\/IAI.66.7.3223-3231.1998","article-title":"Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial","volume":"66","author":"Wedege","year":"1998","journal-title":"Infect Immun"},{"key":"R101","unstructured":"Martin D, Lopez L, Sexton K. The epidemiology of meningococcal disease in New Zealand in 2006. Report from Institute of Environmental Science and Research Ltd, Wellington 2007."},{"key":"R102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban meningococcal BC Vaccine: experiences and contributions from 20 years of application","volume":"9","author":"Sotolongo","year":"2007","journal-title":"MEDICC Rev"},{"key":"R103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1440-1754.2010.01969.x","article-title":"Reducing inequalities with vaccines: New Zealand\u2019s MeNZB vaccine initiative to control an epidemic","volume":"48","author":"Lennon","year":"2012","journal-title":"J Paediatr Child Health"},{"key":"R104","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R105","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1016\/j.vaccine.2012.05.051","article-title":"Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac","volume":"30","author":"Caron","year":"2012","journal-title":"Vaccine"},{"key":"R106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"R107","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"R108","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/IAI.73.7.4070-4080.2005","article-title":"Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination","volume":"73","author":"Fisseha","year":"2005","journal-title":"Infect Immun"},{"key":"R109","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2010.12.039","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","volume":"29","author":"Keiser","year":"2011","journal-title":"Vaccine"},{"key":"R110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2011.11.084","article-title":"Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide","volume":"30","author":"Zollinger","year":"2012","journal-title":"Vaccine"},{"key":"R111","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/CVI.00070-12","article-title":"Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine","volume":"19","author":"Moran","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R112","doi-asserted-by":"crossref","first-page":"886","DOI":"10.4161\/hv.7.8.16086","article-title":"Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants","volume":"7","author":"van der Ley","year":"2011","journal-title":"Hum Vaccin"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.24129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:44:47Z","timestamp":1715168687000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.24129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":112,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,11,3]]},"published-print":{"date-parts":[[2013,6,12]]}},"alternative-id":["10.4161\/hv.24129"],"URL":"https:\/\/doi.org\/10.4161\/hv.24129","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,12]]}}}